Abstract 2126P
Background
The beneficial effects of exercise for cancer patients are well recognized but implemented exercise programs remain scarce, especially for patients during medical treatment. For that reason, we developed a supervised, personalized exercise concept for cancer patients, implemented into a clinical, oncological setting.
Methods
Cancer patients before, during or eventually after their medical treatment with an identified need for exercise could participate in a free of charge exercise intervention for at least three months at the University Hospital Cologne, Germany. We recorded demographic and medical data at enrolment and exercise adherence up to one year.
Results
A sample of n=1.660 patients attended the exercise program. The majority of patients were female (70%), under medical treatment (65%), diagnosed with breast cancer (40%), without metastasis or severe comorbidities (>70%) and on average 54 years old. The median time between diagnosis and exercise participation differed in patients during medical treatment (4 months), patients with metastasis (7 months) and cancer survivors (11 months). Almost one third (31%) discontinued exercise within the first two weeks of participation. Prolonged exercise (median: 19 weeks) was achieved by one third (32%) of the patients. The average exercise adherence was ∼1 session a week with <3% of patients reaching ≥2 sessions a week
Conclusions
To our knowledge, this is the worlds-first report of a professional, supervised exercise program tailored for cancer patients under medical treatment implemented into a clinical setting with >1.600 patients. We described the population that was referred to an exercise program, identified barriers to exercise participation and observed an important mismatch between recommendations and real-world exercise data. Exercise participation was engaged ≥4months after diagnosis and only a third of the patients exercised longer than three months. Almost all patients undercut the well-established exercise recommendations of ≥2 sessions a week. Future implementation concepts should optimize exercise initiation timely after diagnosis and adherence levels due to innovative exercise approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Cologne, Cologne, Germany.
Funding
German Cancer Aid.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06